Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function
Today monoclonal antibodies are widely used in cancer therapy. However, clinical experience as well as translational research into antibodies’ pharmacology and effector mechanisms has identified limitations of antibody therapy, including inefficient effector cell recruitment or initiation of complement-dependent cytotoxicity (CDC). These insights opened alleys for further improvement of antibodies’ immunomodulatory functions. While second generation antibodies were predominantly engineered to reduce immunogenicity, progress in antibody engineering now enables the generation of antibodies with novel interesting features. The introduction of Fc engineering technologies offers the potential to tailor Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), CDC or phagocytosis. Approaches to improve Fc-mediated effector mechanisms by Fc-engineering allow for the design of so-called “fit-for-purpose” antibodies or antibody-derivatives, hopefully overcoming some limitations of current forms of antibody therapy.
- 经典的荧光抗体技术基本原理
- 核苷和核苷酸的标记〔γ-32P〕-ATP标记
- 免疫荧光细胞化学技术
- 全基因组扫描
- 人Fas配体(FasL)酶联免疫分析(ELISA)
- 人弓形虫IgG(Tox IgG)酶联免疫分析(ELISA
- 人工自动免疫(artificial active immunity)
- Structural Basis for HLA-A2 Supertypes
- Micro-Well Phage Replication Assay for Screening Mycobacteria for Resistance to Rifampin and Streptomycin
- In Vitro and In Vivo Models to Study Chemokine Regulation of Angiogenesis